Alivus Life Sciences announced its Q3 FY25 financial results, reflecting strong growth across key financial metrics.
Key Financial Highlights:
- Revenue from Operations: ₹641.84 crore, up 12% YoY from ₹572.80 crore in Q3 FY24.
- Total Income: ₹652.3 crore, a 13.6% YoY increase from ₹574.50 crore.
- Profit Before Tax (PBT): ₹185.14 crore, reflecting a 15% YoY growth from ₹160.68 crore.
- Net Profit (PAT): ₹136.96 crore, a notable 15% YoY rise from ₹118.77 crore.
Operational Highlights:
- The company saw improvements in operating efficiencies and strategic cost management.
- Expenses grew proportionally to revenue, with material costs rising to ₹287.61 crore from ₹243.13 crore.
Nine-Month Performance:
- Revenue: ₹1,761.82 crore, marginally up from ₹1,755.53 crore YoY.
- Net Profit: ₹343.76 crore, a 6% decline YoY due to higher tax expenses.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
